hcplive podcasts
  • MJHLS Brand Logo

© 2020 MJH Life Sciences™ and HCPLive. All rights reserved.

Insights

Best Practices for Improving Patient Outcomes in Older Patient Population

The Importance of Geriatric Care
The Importance of Geriatric Care
Cognitive Concerns in Geriatric Patients
Cognitive Concerns in Geriatric Patients
Mobility Concerns for Geriatric Patients
Mobility Concerns for Geriatric Patients
Medications and Geriatric Care: Ensuring Best Practices
Medications and Geriatric Care: Ensuring Best Practices
Managing Health Conditions in Geriatric Patients
Managing Health Conditions in Geriatric Patients
Coordinating Care for Geriatric Patients
Coordinating Care for Geriatric Patients
Managing Patients Through Other Geriatric Issues
Managing Patients Through Other Geriatric Issues
Quality-of-Life Concerns for Geriatric Patients
Quality-of-Life Concerns for Geriatric Patients
Promoting Healthy Aging
Promoting Healthy Aging

Advances in The Management of Rheumatic Disease

Pathophysiology of Rheumatic Diseases
Pathophysiology of Rheumatic Diseases
Rheumatic Disease Management: Gender and Quality of Life
Rheumatic Disease Management: Gender and Quality of Life
Diagnosis of Rheumatic Diseases
Diagnosis of Rheumatic Diseases
Differential Diagnosis for Rheumatic Diseases
Differential Diagnosis for Rheumatic Diseases
Current Treatment Landscape for Rheumatic Diseases
Current Treatment Landscape for Rheumatic Diseases
Use of Targeted Synthetics in Rheumatic Diseases
Use of Targeted Synthetics in Rheumatic Diseases
Head-to-Head Studies in Rheumatic Diseases
Head-to-Head Studies in Rheumatic Diseases
C-AXSPAND: Nonradiographic Axial Spondyloarthritis
C-AXSPAND: Nonradiographic Axial Spondyloarthritis
Rheumatic Diseases: Biosimilars vs Original Biologics
Rheumatic Diseases: Biosimilars vs Original Biologics
Unmet Needs of Rheumatic Diseases
Unmet Needs of Rheumatic Diseases

Management of Insomnia in the Elderly

Defining and Diagnosing Insomnia Disorder
Defining and Diagnosing Insomnia Disorder
Prevalence of Insomnia Disorder With Age
Prevalence of Insomnia Disorder With Age
Consequences of Poor Sleep in the Elderly
Consequences of Poor Sleep in the Elderly
Non-Pharmacologic Management of Insomnia in the Elderly
Non-Pharmacologic Management of Insomnia in the Elderly
Insomnia Management: Optimizing Nonpharmacologic Methods
Insomnia Management: Optimizing Nonpharmacologic Methods
Pharmacologic Therapy for Insomnia in the Elderly
Pharmacologic Therapy for Insomnia in the Elderly
Wakefulness-Targeted Agents in Insomnia Management
Wakefulness-Targeted Agents in Insomnia Management
Insomnia in the Elderly: Selection of Pharmacologic Therapy
Insomnia in the Elderly: Selection of Pharmacologic Therapy
Treating Insomnia in the Elderly: Orexin Receptor Antagonist
Treating Insomnia in the Elderly: Orexin Receptor Antagonist
Future Management of Insomnia Disorder in Elderly Patients
Future Management of Insomnia Disorder in Elderly Patients

Management of Hypercholesterolemia

The REDUCE-IT Trial and CV Outcomes
The REDUCE-IT Trial and CV Outcomes
Considerations for Treating With Icosapent Ethyl
Considerations for Treating With Icosapent Ethyl
The ODYSSEY Outcomes Trial in CVD
The ODYSSEY Outcomes Trial in CVD
Future Outlook: Treating With PCSK9 Inhibitors
Future Outlook: Treating With PCSK9 Inhibitors

GLP-1 Agonists for the Treatment of Type 2 Diabetes

Type 2 Diabetes and Macrovascular Complications
Type 2 Diabetes and Macrovascular Complications
Impressions of a Patient With T2D and CVD
Impressions of a Patient With T2D and CVD
GLP-1 Agonist Therapy in a Patient With T2D and CVD
GLP-1 Agonist Therapy in a Patient With T2D and CVD
Updates to Diabetes Clinical Practice Guidelines
Updates to Diabetes Clinical Practice Guidelines
Achieving Optimal Glucose Control in Type 2 Diabetes
Achieving Optimal Glucose Control in Type 2 Diabetes
Mechanisms of Action of GLP-1 Agonists in T2D
Mechanisms of Action of GLP-1 Agonists in T2D
Selecting and Using a GLP-1 Agonist to Treat T2D
Selecting and Using a GLP-1 Agonist to Treat T2D
GLP-1 Agonists in T2D: Cardiovascular Outcomes Data
GLP-1 Agonists in T2D: Cardiovascular Outcomes Data
Using GLP-1 Agonists in Patients With T2D and CVD
Using GLP-1 Agonists in Patients With T2D and CVD
GLP-1 Agonists and Weight Loss in T2D
GLP-1 Agonists and Weight Loss in T2D
Novel Strategies for T2D and Comorbid Conditions
Novel Strategies for T2D and Comorbid Conditions

Racial Disparities in Cardiovascular Disease

Understanding America's Health Care Inequality
Understanding America's Health Care Inequality
Income's Effect on Life Expectancy and Health Outcomes
Income's Effect on Life Expectancy and Health Outcomes
Atherosclerotic Cardiovascular Risk for African Americans
Atherosclerotic Cardiovascular Risk for African Americans
How Providers Can Ameliorate Disparities in Health Care
How Providers Can Ameliorate Disparities in Health Care
Diabetes and Heart Disease Among Minority Populations
Diabetes and Heart Disease Among Minority Populations